白敬宇品牌怎么样 申请店铺

我要投票 白敬宇在医疗用品行业中的票数:191 更新时间:2025-04-02
白敬宇是哪个国家的品牌?「白敬宇」是 南京白敬宇制药有限责任公司 旗下著名品牌。该品牌发源于江苏,由创始人陈在1991-07-12期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力白敬宇品牌出海!通过在本页面挂载白敬宇品牌的产品链接和联系邮箱,可以提高白敬宇产品曝光!跨境电商爆单神器,目前只要100元/年哦~

白敬宇怎么样

南京白敬宇制药是一家生产化学原料药及制剂药的综合性制药公司,首批“中华老字号”和江苏省高新技术企业。公司前身“白敬宇眼药厂”1937年在南京成立,“白敬宇”商标于1939年注册,是中国为数极少的民国时期药品注册商标之一,2011年被国家工商总局认定为“中国驰名商标”。公司现有员工近800人,近三年累计产销和利税分别为12.67亿元和1.16亿元,2012年在岗员工人均可支配收入6.22万元。

公司原料药和制剂药生产基地分别位于六合化学工业园区和新港经济技术开发区,两个厂区绿树成荫,均为园区的“园林式工厂”,在2010-2011年先后通过了ISO9001质量体系认证、ISO14001环境管理体系认证以及ISO18001职业健康安全管理体系的认证,在同类企业中处于领先地位。

公司现有注册产品120个,其中原料药27个,制剂药93个。制剂药有片剂、膏剂、胶囊剂、散剂、酊剂、混悬液剂、凝胶剂等15个剂型,主要产品有心脑血管、祛痰镇咳、抗感染、维生素类、眼用膏剂等系列品种,有26个产品进入国家基本药物目录。主要剂型的年最大产量为:片剂80亿片,激素药20亿片,酊水100万升,膏剂6500万支,胶囊剂6.5亿粒,混悬剂45万升、洗剂5万升、散剂9000万包。公司另有24个品规的制剂药产品在12个国家取得了药品注册证书,产品销售到38个国家和地区。公司原料药常年生产盐酸左旋咪唑、酮康唑、氯霉素及酮酸钙等产品,年生产能力大于1000吨。原料药3个主要品种已在欧洲、美国、日本、俄罗斯等国注册销售。

公司的“国际合作”理念决定了公司对原料生产区的环保治理具有超前意识,按照国际惯例,客户在接受产品前必须对企业进行严格的全面质量审计,其中“人的安全和环境保护”是审计的重要项目,因此,供应商审计是公司能够不断进步的动力。2006年至今,原料药厂区共接受国外供应商审计20余次,其中有美国通用、比利时杨森、德国拜耳、西班牙因杜肯等国际性大公司,公司现已成为上述公司的产品供应商。

公司是南京市药品出口产量最大的企业,尤其是制剂药出口更是领先,自营出口1千万美元,出口供货值1亿元人民币。公司以“做好产品、卖好产品”为宗旨,致力于实业拓展。公司的目标是:到2014年,产品制造水平要达到国内一流、国际中等以上标准,以满足不同市场的客户需要,确保企业可持续发展。

Nanjing Baijingyu Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical company that produces chemical raw materials and pharmaceutical preparations. It is one of the first batch of "Chinese time-honored brands" and high-tech enterprises in Jiangsu Province. The company's predecessor, Bai Jingyu eye pharmaceutical factory, was established in Nanjing in 1937. The trademark of Bai Jingyu was registered in 1939. It is one of the few drug registered trademarks in the Republic of China. In 2011, it was recognized as "China's famous trademark" by the State Administration of industry and Commerce. The company has nearly 800 employees. In the past three years, the cumulative production and sales and profits and taxes are RMB 1.267 billion and RMB 116 million respectively. In 2012, the average disposable income of on-the-job employees is RMB 62200. The company's API and pharmaceutical production bases are respectively located in Liuhe chemical industry park and Xingang economic and Technological Development Zone. Both of the two plants are "garden type factories" in the park. From 2010 to 2011, they have passed ISO9001 quality system certification, ISO14001 environmental management system certification and ISO18001 occupational health and safety management system certification, and are in the leading position among similar enterprises First place. The company has 120 registered products, including 27 APIs and 93 pharmaceutical preparations. Preparations include tablets, ointments, capsules, powder, tincture, suspension, gel and other 15 formulations. The main products are cardiovascular, expectorant, antitussive, anti infective, vitamin, eye paste and other varieties. 26 products have entered the national essential drug list. The annual maximum production of main dosage forms is: 8 billion tablets, 2 billion hormone drugs, 1 million liters tincture water, 65 million plasters, 650 million capsules, 450000 liters suspension, 50000 liters lotion and 90 million packages powder. Another 24 pharmaceutical products of the company have obtained drug registration certificates in 12 countries, and the products have been sold to 38 countries and regions. The company's APIs produce levamisole hydrochloride, ketoconazole, chloramphenicol, calcium ketoacid and other products throughout the year, with an annual production capacity of more than 1000 tons. Three main varieties of APIs have been registered and sold in Europe, the United States, Japan, Russia and other countries. The company's concept of "international cooperation" determines that the company has an advanced awareness of environmental protection in the raw material production area. According to international practice, customers must conduct a strict overall quality audit on the enterprise before accepting products. Among them, "human safety and environmental protection" is an important audit project. Therefore, supplier audit is the driving force for the company to make continuous progress. Since 2006, the API plant area has been audited by foreign suppliers for more than 20 times, among which there are international large companies such as general motors of the United States, Janssen of Belgium, Bayer of Germany, induken of Spain, etc. the company has become the product supplier of the above companies. The company is the largest pharmaceutical export enterprise in Nanjing, especially the leading pharmaceutical export, with self export of US $10 million and export supply value of RMB 100 million. With the tenet of "do well in products and sell well in products", the company is committed to industrial development. The company's goal is: by 2014, the product manufacturing level should reach the domestic first-class, international medium-sized and above standards, so as to meet the needs of customers in different markets and ensure the sustainable development of the enterprise.

本文链接: https://brand.waitui.com/ba0510fe3.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

加力扩围发力显效,“两新”政策激发消费活力

4月1日,国家发展改革委消息显示,今年前两个月,“两新”政策进一步发力显效,带动设备工器具购置投资同比增长18%,社会消费品零售总额同比增长4%,继续发挥扩消费、稳投资、促转型、惠民生的重要作用。国家发展改革委指出,“两新”政策有效激发了消费活力。今年超长期特别国债支持消费品以旧换新资金规模增加至3000亿元,相较去年的资金规模翻了一番。首批810亿元资金于1月6日第一时间下达,延续2024年工作基础,扩围支持手机、平板、智能手表手环等数码产品购新。(证券时报)

41分钟前

2024年中国为欧盟汽车进口最大来源国

4月1日,欧盟发布2024年欧盟汽车行业贸易数据,中国以127亿欧元进口额成为欧盟汽车进口最大来源国,欧方称,2019-2024五年间,欧盟自中国进口汽车增幅高达1591.3%;尽管如此,2024年欧盟对华汽车贸易保持顺差,对华出口高达145亿欧元。2024年,欧盟共出口汽车540万辆,进口汽车400万辆。与2019年相比,出口数量下降了13.2%,进口数量则减少了3.0%。(界面)

41分钟前

业绩承诺仅完成6.7%,三鑫医疗高溢价投资面临追偿难

三年累计不低于4200万元的业绩承诺,实际完成280.42万元,完成率仅为6.7%,业绩承诺方暂时无法拿出充足的资金进行股份回购补偿。近日,三鑫医疗一则关于参股公司业绩承诺实现情况专项说明的公告引发众多投资者关注。有受访投行人士分析,高业绩承诺对应的一定是高估值,高估值就意味着高风险,这也提醒上市公司在投资时要紧紧围绕自身战略进行布局,真正做好风险控制。(上证报)

41分钟前

全球风险资产震荡,市场静待关税靴子落地

美国即将于4月2日启动对等关税,引发市场连锁反应。美股三大指数上周集体下挫,亚太市场同步承压,避险资金则推动黄金现货价格触及3149.03美元/盎司的历史高位。随着政策实施时点临近,市场对美国经济政策框架的能见度逐步提升。部分机构表示,政策的可预测性上升,积极信号正在酝酿;也有机构对风险资产的表现感到担忧。尽管短期波动性骤增,但市场普遍认为,4月2日将为接下来几个月的金融市场走向定下基调。(中证网)

41分钟前

中信建投:电解铝强调清洁能源代替,绿证市场有望加速成长

36氪获悉,中信建投证券研报显示,近期,工业和信息化部等十部门发布关于印发《铝产业高质量发展实施方案(2025—2027年)》。具体来看,《方案》鼓励企业参与光伏、风电等可再生能源和氢能、储能系统开发建设。推进氢氧化铝焙烧、铝用阳极焙烧环节实施清洁能源替代。在我国能耗双控转型的背景下,高耗能企业的清洁用能替代需求有望持续增长,有助于绿电、绿证市场的加速发展,有利于风光项目环境价值的兑现。

41分钟前

本页详细列出关于丽珠医药LIVZON的品牌信息,含品牌所属公司介绍,丽珠医药LIVZON所处行业的品牌地位及优势。
咨询